Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States.
- DOI
- 10.1161/jaha.123.029042
- Published
- 2024 Feb 20
- Container
- Journal of the American Heart Association
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1161/jaha.123.029042,
title = {Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States.},
author = {Reifsnider OS and Tafazzoli A and Linden S and Ishak J and Rakonczai P and Stargardter M and Kuti E},
year = {2024},
journal = {Journal of the American Heart Association},
doi = {10.1161/jaha.123.029042},
url = {https://doi.org/10.1161/jaha.123.029042}
}RIS
TY - JOUR TI - Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States. AU - Reifsnider OS AU - Tafazzoli A AU - Linden S AU - Ishak J AU - Rakonczai P AU - Stargardter M AU - Kuti E PY - 2024 JO - Journal of the American Heart Association DO - 10.1161/jaha.123.029042 UR - https://doi.org/10.1161/jaha.123.029042 ER -
APA
OS, R., A, T., S, L., J, I., P, R., M, S., & E, K. (2024). Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States.. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.029042
Source records
- pubmed · retrieved 2026-09-26T00:34:43.100Z